Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

236 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Why do anti-tumor necrosis factor antibodies work in Crohn's disease?
Sands BE. Sands BE. Rev Gastroenterol Disord. 2004;4 Suppl 3:S10-7. Rev Gastroenterol Disord. 2004. PMID: 15580148 Review.
Variation in treatment of patients with inflammatory bowel diseases at major referral centers in the United States.
Ananthakrishnan AN, Kwon J, Raffals L, Sands B, Stenson WF, McGovern D, Kwon JH, Rheaume RL, Sandler RS. Ananthakrishnan AN, et al. Clin Gastroenterol Hepatol. 2015 Jun;13(6):1197-200. doi: 10.1016/j.cgh.2014.11.020. Epub 2014 Nov 21. Clin Gastroenterol Hepatol. 2015. PMID: 25460565 Free PMC article.
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M, Löfberg R, Quary A, Sands B, Sood A, Watermeyer G, Lashner B, Lémann M, Plevy S, Reinisch W, Schreiber S, Siegel C, Targan S, Watanabe M, Feagan B, Sandborn WJ, Colombel JF, Travis S. D'Haens GR, et al. Am J Gastroenterol. 2011 Feb;106(2):199-212; quiz 213. doi: 10.1038/ajg.2010.392. Epub 2010 Nov 2. Am J Gastroenterol. 2011. PMID: 21045814 Review.
Careful consideration should be given to the reasons for loss of response. There are insufficient data to make recommendations on when to stop anti-TNF therapy. ...
Careful consideration should be given to the reasons for loss of response. There are insufficient data to make recommendations on whe …
Review article: practical management of inflammatory bowel disease patients taking immunomodulators.
Siegel CA, Sands BE. Siegel CA, et al. Aliment Pharmacol Ther. 2005 Jul 1;22(1):1-16. doi: 10.1111/j.1365-2036.2005.02520.x. Aliment Pharmacol Ther. 2005. PMID: 15963074 Review.
Furthermore, once initiating therapy, patients need to be monitored appropriately for evidence of efficacy and toxicity. This review includes the rationale behind recommendations for the management and monitoring of patients using immunomodulators. ...With appropriate moni …
Furthermore, once initiating therapy, patients need to be monitored appropriately for evidence of efficacy and toxicity. This review …
Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease.
Sands BE, Winston BD, Salzberg B, Safdi M, Barish C, Wruble L, Wilkins R, Shapiro M, Schwertschlag US; RHIL-11 Crohn's Study group. Sands BE, et al. Aliment Pharmacol Ther. 2002 Mar;16(3):399-406. doi: 10.1046/j.1365-2036.2002.01179.x. Aliment Pharmacol Ther. 2002. PMID: 11876692 Clinical Trial.
Medical therapy of steroid-resistant Crohn's disease.
Sands BE. Sands BE. Can J Gastroenterol. 2000 Sep;14 Suppl C:33C-37C. doi: 10.1155/2000/805015. Can J Gastroenterol. 2000. PMID: 11023559 Review.
Approximately 20% of patients fail to respond to initial treatment with steroids, while 36% of patients may be considered steroid dependent. ...Clearer distinctions may be drawn between those who fail to respond to initial treatment with corticosteroids and those wh …
Approximately 20% of patients fail to respond to initial treatment with steroids, while 36% of patients may be considered steroid dep …
Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease.
Sands BE, Bank S, Sninsky CA, Robinson M, Katz S, Singleton JW, Miner PB, Safdi MA, Galandiuk S, Hanauer SB, Varilek GW, Buchman AL, Rodgers VD, Salzberg B, Cai B, Loewy J, DeBruin MF, Rogge H, Shapiro M, Schwertschlag US. Sands BE, et al. Gastroenterology. 1999 Jul;117(1):58-64. doi: 10.1016/s0016-5085(99)70550-0. Gastroenterology. 1999. PMID: 10381910 Clinical Trial.
The thrombocytopoietic effect of rhIL-11 seems to be both dose and schedule dependent and may be minimized with retained clinical benefit in Crohn's disease at 16 microgram. kg-1. wk-1 given in 2 equal doses....
The thrombocytopoietic effect of rhIL-11 seems to be both dose and schedule dependent and may be minimized with retained clini …
Novel therapies for inflammatory bowel disease.
Sands BE. Sands BE. Gastroenterol Clin North Am. 1999 Jun;28(2):323-51. doi: 10.1016/s0889-8553(05)70059-5. Gastroenterol Clin North Am. 1999. PMID: 10372271 Review.
When a drug appears to be less effective than preclinical models suggest, can failures in effectiveness from delivery or dosing be differentiated? ...Clinicians are only just beginning to recognize subclinical markers of response, and it may soon be possible …
When a drug appears to be less effective than preclinical models suggest, can failures in effectiveness from delivery or dosing be
New biologic agents: a critical appraisal.
Sands BE. Sands BE. Curr Gastroenterol Rep. 1999 Dec;1(6):470-5. doi: 10.1007/s11894-999-0005-7. Curr Gastroenterol Rep. 1999. PMID: 10980988 Review.
The notable efficacy of infliximab also sets a benchmark against which future biologic agents might be compared. Although it will be many years until active comparisons of these agents are made through clinical trials, sufficient clinical data is now available for c …
The notable efficacy of infliximab also sets a benchmark against which future biologic agents might be compared. Although it will …
236 results
Jump to page
Feedback